The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
(Reuters) -The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health ...
Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...
Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration has approved JOURNAVX, an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor ...
Fintel reports that on January 30, 2025, Wells Fargo downgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
The FDA approved Vertex Pharmaceuticals’ Journavx, a new non-opioid pain pill for short-term pain. While safer than opioids, ...
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...
Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...